|Registry of biomedical companies:
   [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [Z] 510 active entries
Level 9, 305 Grattan Street
Melbourne VIC 3000
Phone: +61 (0)3 8559 7321
Cell Therapies Pty Ltd is a contract development and manufacturing organization (CDMO) that manufactures and deploys advanced cell-based therapies to the global market.
Established in 2003, Cell Therapies Pty Ltd is one of the most experienced cGMP compliant manufacturers for cell therapies, gene therapies, cellular immunotherapies and regenerative medicine products globally. Working closely with its clinical and research collaborators at the Peter MacCallum Cancer Centre (http://petermac.org), Cell Therapies Pty Ltd provides its clients with needle-to-needle solutions for apheresis collection, GMP manufacturing, cryopreservation, state of the art imaging (real-time in vivo cell tracking) and clinical trial implementation.
Cell Therapies Pty Ltd has a ten (10) clean room GMP facility located in Melbourne, Australia at the heart of the biomedical precinct, with access to hospitals, research institutes and universities to support development, translation and patient access. This facility holds both clinical trial and commercial supply manufacturing licenses from the Australian Therapeutic Goods Administration (TGA), ensuring the products from our facility meet global regulatory standards.
We have a proven track record of delivering cell-based therapeutic products to patients from early phase clinical trials through to commercial supply according to the requirements of local and international regulators. We have also established multi continental manufacturing networks to support trials concurrently registered in Europe, Asia and North America and have an enviable track record for efficient and successful tech transfer inbound and outbound to our collaborators.
Please contact us through our website (http://www.celltherapies.com.au) to discuss potential collaborations.
Last update of this entry: November 15, 2019